D-FISH results for CD34+ and CD34+38- cells enriched from CML samples before and after 72 hours of exposure to IM and/or dasatinib
. | . | CD34+ after IM/Das BCR-ABL+ cells/total cells (%) . | . | . | CD34+CD38- after IM/Das BCR-ABL+ cells/total cells (%) . | . | ||
|---|---|---|---|---|---|---|---|---|
| Patient no. . | CD34+ pre-IM/Das BCR-ABL+ cells/total cells (%) . | IM . | Dasatinib . | CD34+CD38- before IM/Das BCR-ABL+ cells/total cells (%) . | IM . | Dasatinib . | ||
| 1 | 65/78 (83) | 46/72 (64) | 52/78 (67) | ND | ND | ND | ||
| 2 | 443/443 (100) | 73/78 (94) | 86/87 (99) | 132/132 (100) | ND | 87/89 (98) | ||
| 3 | 333/336 (99) | 35/35 (100) | 332/334 (99) | 355/357 (99) | ND | 207/210 (99) | ||
| 4 | 277/314 (88) | ND | ND | 37/39 (95) | 27/28 (96) | 31/32 (97) | ||
| 5 | 221/253 (87) | ND | ND | 357/393 (85) | 91/107 (85) | 28/30 (93) | ||
| 6 | 115/118 (97.5) | ND | ND | ND | ND | ND | ||
| 7 | 166/166 (100) | ND | 253/253 (100) | 115/115 (100) | 230/230 (100) | 167/169 (99) | ||
| 8 | 160/176 (90.9) | ND | ND | ND | ND | ND | ||
| 9 | 47/47 (100) | ND | ND | 56/58 (97) | 125/126 (99) | ND | ||
| 10 | 501/555 (90.3) | ND | ND | ND | ND | ND | ||
. | . | CD34+ after IM/Das BCR-ABL+ cells/total cells (%) . | . | . | CD34+CD38- after IM/Das BCR-ABL+ cells/total cells (%) . | . | ||
|---|---|---|---|---|---|---|---|---|
| Patient no. . | CD34+ pre-IM/Das BCR-ABL+ cells/total cells (%) . | IM . | Dasatinib . | CD34+CD38- before IM/Das BCR-ABL+ cells/total cells (%) . | IM . | Dasatinib . | ||
| 1 | 65/78 (83) | 46/72 (64) | 52/78 (67) | ND | ND | ND | ||
| 2 | 443/443 (100) | 73/78 (94) | 86/87 (99) | 132/132 (100) | ND | 87/89 (98) | ||
| 3 | 333/336 (99) | 35/35 (100) | 332/334 (99) | 355/357 (99) | ND | 207/210 (99) | ||
| 4 | 277/314 (88) | ND | ND | 37/39 (95) | 27/28 (96) | 31/32 (97) | ||
| 5 | 221/253 (87) | ND | ND | 357/393 (85) | 91/107 (85) | 28/30 (93) | ||
| 6 | 115/118 (97.5) | ND | ND | ND | ND | ND | ||
| 7 | 166/166 (100) | ND | 253/253 (100) | 115/115 (100) | 230/230 (100) | 167/169 (99) | ||
| 8 | 160/176 (90.9) | ND | ND | ND | ND | ND | ||
| 9 | 47/47 (100) | ND | ND | 56/58 (97) | 125/126 (99) | ND | ||
| 10 | 501/555 (90.3) | ND | ND | ND | ND | ND | ||
Das indicates dasatinib; ND, not done.